FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096009478> ?p ?o ?g. }

• W2096009478 endingPage "518" @default.
• W2096009478 startingPage "513" @default.
• W2096009478 abstract "To investigate the role of brachytherapy in intermediate- and high-risk prostate cancer. We report our results and a review of published studies.Between March 1999 and April 2003, 300 patients were treated with low dose rate 1-125 interstitial prostate brachytherapy and followed prospectively. The patients were stratified into low-, intermediate- and high-risk groups and received brachytherapy alone or in combination with external beam radiotherapy (EBRT) and/or neoadjuvant androgen deprivation (NAAD). One hundred and forty-six patients were classified as low risk, 111 as intermediate risk and 43 as high risk. Biochemical freedom from disease and prostate-specific antigen (PSA) nadirs were analysed for risk groups and for treatment received in each risk group.The median follow-up was 45 months (range 33-82 months) with a mean age of 63 years. Actuarial 5-year biochemical relapse-free survival for the low-risk group was 96%, 89% for the intermediate-risk group and 93% for the high-risk group. When stratified by treatment group, low-risk patients had a 5-year actuarial biochemical relapse-free survival of 94% for brachytherapy alone (n=77), 92% for NAAD and brachytherapy (n=66) and 100% for NAAD, EBRT and brachytherapy (n=3). In the intermediate-risk patients, biochemical relapse-free survival was 93% for brachytherapy alone (n=15), 94% for NAAD and brachytherapy (n=67), 75% for EBRT and brachytherapy (n=4) and 92% for NAAD, EBRT and brachytherapy (n=25). In the high-risk group, biochemical relapse-free survival was 100% for brachytherapy alone (n=2), 88% for NAAD and brachytherapy (n=7), 80% for EBRT and brachytherapy (n=5) and 96% for NAAD, EBRT and brachytherapy (n=29). Overall 3- and 4-year PSA = 0.5 ng/ml were achieved by 71 and 86%, respectively, and a 4-year PSA = 0.2 ng/ml was achieved by 63%.Although the role of combination treatment with pelvic EBRT and androgen therapy is not clear, our early results show that many patients with intermediate- and high-risk disease have excellent results with brachytherapy." @default.
• W2096009478 created "2016-06-24" @default.
• W2096009478 creator A5026151822 @default.
• W2096009478 creator A5035257655 @default.
• W2096009478 creator A5068373079 @default.
• W2096009478 creator A5086077558 @default.
• W2096009478 date "2006-09-01" @default.
• W2096009478 modified "2023-09-25" @default.
• W2096009478 title "Interstitial Low Dose Rate Brachytherapy for Prostate Cancer — A Focus on Intermediate- and High-risk Disease" @default.
• W2096009478 cites W1522431258 @default.
• W2096009478 cites W1536965801 @default.
• W2096009478 cites W1563942959 @default.
• W2096009478 cites W1969027862 @default.
• W2096009478 cites W1975096840 @default.
• W2096009478 cites W1979803485 @default.
• W2096009478 cites W1988456256 @default.
• W2096009478 cites W1997391244 @default.
• W2096009478 cites W2007494001 @default.
• W2096009478 cites W2021220421 @default.
• W2096009478 cites W2026118965 @default.
• W2096009478 cites W2028159286 @default.
• W2096009478 cites W2059487933 @default.
• W2096009478 cites W2062416248 @default.
• W2096009478 cites W2074421032 @default.
• W2096009478 cites W2078572622 @default.
• W2096009478 cites W2084437251 @default.
• W2096009478 cites W2089403922 @default.
• W2096009478 cites W2117792530 @default.
• W2096009478 cites W2117849419 @default.
• W2096009478 cites W2118157857 @default.
• W2096009478 cites W2123420657 @default.
• W2096009478 cites W2126645707 @default.
• W2096009478 cites W2134766389 @default.
• W2096009478 cites W2159404318 @default.
• W2096009478 cites W2163120057 @default.
• W2096009478 cites W2172038823 @default.
• W2096009478 cites W2209020482 @default.
• W2096009478 cites W2316095838 @default.
• W2096009478 cites W2329611551 @default.
• W2096009478 cites W2402343233 @default.
• W2096009478 cites W357469078 @default.
• W2096009478 doi "https://doi.org/10.1016/j.clon.2006.05.005" @default.
• W2096009478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16969980" @default.
• W2096009478 hasPublicationYear "2006" @default.
• W2096009478 type Work @default.
• W2096009478 sameAs 2096009478 @default.
• W2096009478 citedByCount "18" @default.
• W2096009478 countsByYear W20960094782012 @default.
• W2096009478 countsByYear W20960094782014 @default.
• W2096009478 countsByYear W20960094782015 @default.
• W2096009478 crossrefType "journal-article" @default.
• W2096009478 hasAuthorship W2096009478A5026151822 @default.
• W2096009478 hasAuthorship W2096009478A5035257655 @default.
• W2096009478 hasAuthorship W2096009478A5068373079 @default.
• W2096009478 hasAuthorship W2096009478A5086077558 @default.
• W2096009478 hasConcept C121608353 @default.
• W2096009478 hasConcept C126322002 @default.
• W2096009478 hasConcept C126894567 @default.
• W2096009478 hasConcept C141071460 @default.
• W2096009478 hasConcept C143998085 @default.
• W2096009478 hasConcept C2775908122 @default.
• W2096009478 hasConcept C2776235491 @default.
• W2096009478 hasConcept C2777416452 @default.
• W2096009478 hasConcept C2777899217 @default.
• W2096009478 hasConcept C2778648096 @default.
• W2096009478 hasConcept C2780192828 @default.
• W2096009478 hasConcept C509974204 @default.
• W2096009478 hasConcept C71924100 @default.
• W2096009478 hasConceptScore W2096009478C121608353 @default.
• W2096009478 hasConceptScore W2096009478C126322002 @default.
• W2096009478 hasConceptScore W2096009478C126894567 @default.
• W2096009478 hasConceptScore W2096009478C141071460 @default.
• W2096009478 hasConceptScore W2096009478C143998085 @default.
• W2096009478 hasConceptScore W2096009478C2775908122 @default.
• W2096009478 hasConceptScore W2096009478C2776235491 @default.
• W2096009478 hasConceptScore W2096009478C2777416452 @default.
• W2096009478 hasConceptScore W2096009478C2777899217 @default.
• W2096009478 hasConceptScore W2096009478C2778648096 @default.
• W2096009478 hasConceptScore W2096009478C2780192828 @default.
• W2096009478 hasConceptScore W2096009478C509974204 @default.
• W2096009478 hasConceptScore W2096009478C71924100 @default.
• W2096009478 hasIssue "7" @default.
• W2096009478 hasLocation W20960094781 @default.
• W2096009478 hasLocation W20960094782 @default.
• W2096009478 hasOpenAccess W2096009478 @default.
• W2096009478 hasPrimaryLocation W20960094781 @default.
• W2096009478 hasRelatedWork W2083802215 @default.
• W2096009478 hasRelatedWork W2085529113 @default.
• W2096009478 hasRelatedWork W2120395260 @default.
• W2096009478 hasRelatedWork W2138863125 @default.
• W2096009478 hasRelatedWork W2165532162 @default.
• W2096009478 hasRelatedWork W2597301728 @default.
• W2096009478 hasRelatedWork W2789553788 @default.
• W2096009478 hasRelatedWork W2809846915 @default.
• W2096009478 hasRelatedWork W2946095553 @default.
• W2096009478 hasRelatedWork W4383700443 @default.
• W2096009478 hasVolume "18" @default.
• W2096009478 isParatext "false" @default.

• next